BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
SPH4336: trial readouts and FDA decisions
3 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 1 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Shanghai Pharmaceuticals Holding Co., Ltd. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12-01 est. | P2/P3 | Shanghai Pharmaceuticals Holding Co., Ltd | NCT05860465 Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer | Locally Advanced or Metastatic Breast Cancer | recruiting | 254 |
| 2026-12-31 est. | P2 | Shanghai Pharmaceuticals Holding Co., Ltd | NCT05872347 Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases. | Breast Cancer Brain Metastases | recruiting | 52 |
| 2026-12-31 est. | P1/P2 | Shanghai Pharmaceuticals Holding Co., Ltd | NCT05944224 A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors. | Advanced Solid Tumors | recruiting | 63 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-05-31 est. | P2/P3 | Shanghai Pharmaceuticals Holding Co., Ltd | NCT05744687 Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer | Locally Advanced or Metastatic Breast Cancer | recruiting | 374 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.